Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

Abstract

CDI and SDI are outcomes of interest for clinical trials and for long-term follow-up of participants with RMS. Monitoring CDI and SDI in addition to disability worsening may facilitate understanding of the therapeutic benefit of RMS treatments.